Non-alcoholic steatohepatitis (NASH), is one of the common liver diseases, often called silent liver disease. The major feature in NASH is fat deposition in the liver, along with inflammation.
NASH is projected to lead the cause of liver transplantation in the U.S. in the coming years. Some major factors such as higher prevalence of NASH, expected launch of pipeline drugs, and higher number of unmet needs drive the growth of this market. However, poor diagnosis of NASH due to the lack of ideal diagnostic technologies limit the growth of the NASH market.
At present, vitamin E & pioglitazone segment dominates the non-alcoholic steatohepatitis (NASH) market, due to efficacy.
Asia-Pacific presents lucrative opportunities for the key players operating in the non-alcoholic steatohepatitis (NASH) market. Some factors such as growth in diagnostic techniques, rapid rise in prevalence NASH, growth in economies, and increase in demand for NASH therapeutics drive the market growth in Asia-Pacific.
In 2018, the global Nonalcoholic Steatohepatitis (NASH) market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Nonalcoholic Steatohepatitis (NASH) status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Nonalcoholic Steatohepatitis (NASH) development in United States, Europe and China.
The key players covered in this study
Market segment by Type, the product can be split into
Vitamin E & Pioglitazone
Selonsertib & Cenicriviroc
Market segment by Application, split into
Market segment by Regions/Countries, this report covers
Central & South America
The study objectives of this report are:
To analyze global Nonalcoholic Steatohepatitis (NASH) status, future forecast, growth opportunity, key market and key players.
To present the Nonalcoholic Steatohepatitis (NASH) development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Nonalcoholic Steatohepatitis (NASH) are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.